Further to the announcement made by Shire plc on January 8, 2019, Shire today announces that, following an application by Shire, the UK Listing Authority has cancelled the listing of Shire Shares on the premium listing segment of the Official List and the London Stock Exchange has cancelled the trading of Shire Shares on the London Stock Exchange’ s main market...
January 8, 2019– Shire plc. Notification of transactions by persons discharging managerial responsibilities. For further information please contact:.
RNS Number: 5418 M Citigroup Derivatives Markets Inc 08 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 5266 M Goldman Sachs& Co. LLC 08 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS. Rule 8.5 of the Takeover Code.
RNS Number: 5253 M J.P. Morgan Securities LLC 08 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. On May 8, 2018, Shire plc and Takeda Pharmaceutical Company Limited announced that they had reached agreement on the terms of a recommended cash and share...
January 7, 2019– Shire plc. For further information please contact:. Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.
RNS Number: 4164 M Citigroup Global Markets Inc. 07 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY. A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE. Rule 8.3 of the Takeover Code.
RNS Number: 4008 M Citigroup Derivatives Markets Inc 07 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 3811 M J.P. Morgan Securities LLC 07 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 3749 M Nomura International PLC 07 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2795 M Citigroup Global Markets Inc. 04 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2776 M Citigroup Derivatives Markets Inc 04 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2472 M J.P. Morgan Securities LLC 04 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 1553 M Citigroup Derivatives Markets Inc 03 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 1442 M Takeda Pharmaceutical Company Ltd 03 January 2019. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Osaka, Japan- January 3, 2019- Takeda Pharmaceutical Company Limited notes Shire plc's...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Applications have been made for the suspension of trading in Shire Shares on the London Stock Exchange's main market for listed securities and the...
RNS Number: 1299 M J.P. Morgan Securities LLC 03 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 1274 M Nomura International PLC 03 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
Shire Plc
SHP.L
Shire Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    917.10M

Company Profile

Drugs group Shire Pharmaceuticals is best known for the attention deficit disorder treatments Adderall and Vyvanse. Founded in 1986 and became a listed company in 1996.

Classification

Market Indices-

Locations

HQ
Miesian Plaza
50-58 Baggot Street Lower
Blocks 2 & 3
2
Dublin
Watchlist